Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in multiple solid tumors
- New trial
Multiple solid tumors
Phase 1b [225Ac]Ac-AKY-1189 Nectin-4 Radiopharmaceutical, a Nectin-4-directed alpha emitter.
This first-in-human, two-part study led by Aktis Oncology evaluates the safety and maximum tolerated dose of [225Ac]Ac-AKY-1189 monotherapy in patients with advanced or metastatic solid tumors. Conducted at Grand…
NCT07020117 First-in-human - New trial
Multiple solid tumors
Phase 1 Study of BL-M17D1: HER2-directed mAb Auristatin (tubulin inhibitor) ADC
This Phase 1 open-label trial, sponsored by SystImmune Inc., assesses BL-M17D1 administered every three weeks in patients with HER2-expressing or HER2-mutated advanced/metastatic solid tumors. The study includes…
NCT06714617 First-in-human - New trial
Multiple solid tumors
Phase 1/2 trial of CGT4859, an FGFR2/3 inhibitor, in advanced solid tumors
This open-label study evaluates the safety, dosing, and antitumor activity of oral CGT4859 administered via dose escalation and expansion in adults with unresectable or metastatic intrahepatic cholangiocarcinoma and…
NCT06777316 First-in-human - New trial
Multiple solid tumors
Phase III RT Trial: VLDRT as ionizing radiation for DNA damage in indolent lymphomas
Memorial Sloan Kettering Cancer Center is investigating whether very low dose radiotherapy (4 Gy in 1-2 fractions) is as effective as standard treatment (24 Gy in 12 fractions) for untreated indolent B-cell lymphomas…
NCT07029217 Registrational - New trial
Multiple solid tumors
Phase 1/2 trial of AVZO-023, a CDK4/CDK6 inhibitor.
This trial by Avenzo Therapeutics assesses AVZO-023 safety and antitumor activity as monotherapy and in combination with AVZO-021, fulvestrant, or letrozole in patients with advanced solid tumors including HR+/HER2-…
NCT06998407 First-in-human - New trial
Multiple solid tumors
Phase 1 VIR-5525 EGFR-directed T-cell engager trial.
This first-in-human study evaluates VIR-5525 as monotherapy and with pembrolizumab in dose-escalation and expansion cohorts for locally advanced or metastatic solid tumors expressing EGFR, including HNSCC, CRC, and…
NCT06960395 First-in-human - New trial
Multiple solid tumors
Phase 1 study of NKT5097, a CDK2/CDK4/6 inhibitor for advanced solid tumors.
This open-label study evaluates the safety, tolerability, and pharmacokinetics of NKT5097 in adults with advanced/metastatic solid tumors, including breast cancer and CCNE1-amplified cases. The trial features dose…
NCT07029399 First-in-human - New trial
Multiple solid tumors
Phase 1 trial of [Ga-68]MTP220, targeted PET tracer.
This first-in-human, single-arm open-label study evaluates the safety and imaging efficacy of a one-time injection of [Ga-68]MTP220 followed by serial PET/CT scans during a 2.5-hour session. It enrolls newly…
NCT07026981 First-in-human - New trial
Multiple solid tumors
Phase 1 Tirbanibulin Ointment DNA synthesis inhibitor trial for keratinocyte carcinomas
This trial evaluates fractional laser therapy alone versus in combination with tirbanibulin ointment for treating squamous and basal cell carcinomas. Eligible first-line patients with superficial to invasive…
NCT07010692 Exploratory - New trial
Multiple solid tumors
Phase 1/2a VS-7375 trial: KRAS G12D inhibitor for advanced solid tumors
This open-label study evaluates VS-7375 alone or with cetuximab in patients with advanced metastatic solid tumors harboring KRAS G12D mutations, including pancreatic, lung, and colorectal cancers. The trial aims to…
NCT07020221 First-in-human - New trial
Multiple solid tumors
Phase 1 PF-08046031 anti-CD228 ADC trial for advanced melanoma and solid tumors.
This open-label Phase 1 study evaluates PF-08046031 as monotherapy in adults with metastatic melanoma and other advanced solid tumors lacking approved treatment options. The trial, conducted by Pfizer at sites…
NCT06799533 First-in-human - New trial
Multiple solid tumors
Phase 1 ARC101 CLDN6-directed T-cell receptor engager trial in advanced cancers.
A first-in-human trial assessing escalating doses and expansion cohorts of ARC101 as monotherapy in patients with advanced or metastatic solid tumors, including testicular and ovarian cancers expressing CLDN6. This…
NCT06672185 First-in-human - New trial
Multiple solid tumors
Phase 1/2 ETX-636 pan-mutant-selective PI3Kα inhibitor trial
This open-label study evaluates ETX-636 as monotherapy in advanced solid tumors with PIK3CA mutations and in combination with fulvestrant in HR+/HER2- metastatic breast cancer. Conducted by Ensem Therapeutics in…
NCT06993844 First-in-human - New trial
Multiple solid tumors
Phase I NeoVax Personalized Neo-Antigen Vaccine Targeting Patient-Specific Tumor Mutations
This study evaluates the safety and immune response of NeoVax combined with poly ICLC and nivolumab in patients with metastatic or refractory melanoma, breast cancer, and non-small cell lung cancer. Conducted at Fred…
NCT05098210 Exploratory - Trial result Spotlight
Multiple solid tumors
Mismatch-Repair Gene Shapes Immune Checkpoint Blocker Outcomes: MLH1/MSH2 Hit 40-46% CR, PMS2 Falls to 9% and 20-mo OS
In a retrospective MSK-IMPACT series (NCT01775072), 132 patients with Lynch syndrome and advanced solid tumors—including colorectal cancer (35%), genitourinary cancers (14%), and pancreatic or biliary cancers…
NCT01775072 - New trial
Multiple solid tumors
Phase 1 trial of ZZ06, an EGFR mAb, in advanced EGFR-positive solid tumors.
This open-label, multicenter study determines the maximum tolerated dose and characterizes safety, pharmacokinetics, immunogenicity, pharmacodynamics, and preliminary antitumor activity of ZZ06 as a single agent in…
NCT04412616 First-in-human - New trial
Multiple solid tumors
Phase 1 study of ADCE-T02, a tissue factor targeted antibody-drug conjugate in advanced solid tumors.
This first-in-human, dose-escalation study evaluates ADCE-T02 as a single agent in patients with unresectable advanced solid tumors who have progressed on ≥2 lines of therapy. The trial aims to determine the maximum…
NCT06597721 First-in-human - New trial
Multiple solid tumors
Phase 1a/1b study of DR-0202, a Dectin-1 and CD20 bispecific mAb in refractory carcinomas.
This multicenter, open-label study evaluates the safety, tolerability, and activity of DR-0202 administered every two weeks in patients with advanced or metastatic, relapsed or refractory carcinomas who have…
NCT06999187 First-in-human - New trial
Multiple solid tumors
Phase 1b DF6215 trial: IL-2 variant immune modulator
This open‐label study evaluates DF6215 as monotherapy and with pembrolizumab in patients with advanced solid tumors, including melanoma and ovarian cancer, to assess safety, tolerability, pharmacokinetics, and early…
NCT06108479 - New trial
Multiple solid tumors
Phase I Trial: NovoTTF-200M—Electromagnetic Therapy for Refractory Spinal Metastasis
This Phase I study at M.D. Anderson evaluates the safety of NovoTTF-200M and NovoTTF-200A devices delivering electromagnetic therapy alone or with standard treatment in patients with refractory spinal metastasis.…
NCT06906900 - New trial
Multiple solid tumors
Phase 1 study of SLV-154, small molecule inhibitor with undefined MOA.
This Phase 1 dose-escalation study by Solve Therapeutics in Saint Louis evaluates SLV-154 as a monotherapy for patients with metastatic, progressive solid tumors including SCCHN, sarcoma, breast, cervical,…
NCT06771219 - New trial
Multiple solid tumors
Phase 1/1b trial of BMS-986488, undefined MOA small molecule inhibitor.
This trial evaluates BMS-986488 as monotherapy or in combination with adagrasib, cetuximab, or nivolumab to assess safety, tolerability, and initial anti-tumor activity in patients with advanced, unresectable solid…
NCT06764771 - New trial
Multiple solid tumors
Phase I Trial of XL309, a USP1 (BRCA/HRD directed) Inhibitor in Advanced Tumors
This open-label, multicenter Phase I study led by Exelixis evaluates XL309 as a single agent and with olaparib in patients with advanced solid tumors, including HRR-mutant, CRPC, breast, pancreatic, and HGSOC…
NCT05932862 - New trial
Multiple solid tumors
Phase 1/2 Study of anti-KRAS G12V mTCR Cells, a Targeted KRAS G12V TCR-T Therapy
National Cancer Institute is evaluating safety and tumor response of anti-KRAS G12V mTCR cells given with chemotherapy and cytokine treatment in adults with metastatic NSCLC, gastric, pancreatic, and colorectal…
NCT03190941 - New trial
Multiple solid tumors
Phase 1/2a PTT-936 Trial of ALPK1 Activator in Solid Tumors
This study evaluates the safety, dosage, and efficacy of PTT-936, an ALPK1 activator, administered weekly as monotherapy or with anti-PD-1/L1 every three weeks. It enrolls patients with locally advanced or metastatic…
NCT06244992 - New trial
Multiple solid tumors
Phase 1/2 study of LY3537982, a KRAS G12C inhibitor, in advanced solid tumors.
This open-label trial, sponsored by Eli Lilly and Company, evaluates LY3537982 alone or with agents like pembrolizumab in patients with unresectable advanced or metastatic solid tumors harboring KRAS G12C mutations,…
NCT04956640 - New trial
Multiple solid tumors
Phase 1 FIH XB010, a 5T4-targeted tubulin inhibitor ADC
This dose-escalation and expansion study evaluates the safety, pharmacokinetics, immunogenicity, and preliminary antitumor activity of XB010 as a single agent or with pembrolizumab in patients with locally advanced…
NCT06545331 - New trial
Multiple solid tumors
Phase 1 VT3989 Transcription Factor Inhibitor Trial
This multi-center, open-label study evaluates VT3989 given alone or with immunotherapy (nivolumab/ipilimumab) or targeted therapy (osimertinib) in patients with advanced or metastatic mesothelioma and solid tumors…
NCT04665206 - New trial
Multiple solid tumors
Phase 1b/2 Trial of STC-15, a METTL3 inhibitor
This open-label, non-randomized, multi-cohort study evaluates the safety, tolerability, and antitumor activity of STC-15 plus toripalimab in advanced NSCLC, melanoma, endometrial, and head and neck cancers after…
NCT06975293 - New trial
Multiple solid tumors
Phase 1 trial of BMS-986500, undisclosed target inhibitor in advanced cancers.
This first-in-human study by Bristol-Myers Squibb evaluates BMS-986500 as monotherapy or combined with palbociclib and fulvestrant in advanced solid tumors, including ovarian cancer with CCNE1 amplification and…
NCT06997029
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.